Tweaked bacteria genes activate heart cells in mice
Researchers have shown that engineered bacterial genes coding for sodium ion channels could lead to novel gene therapies for electrical heart diseases.
List view / Grid view
Researchers have shown that engineered bacterial genes coding for sodium ion channels could lead to novel gene therapies for electrical heart diseases.
A new CAR T-cell therapy for B-cell cancers promises to reduce the antigen escape currently found in therapies that only target CD19.
The length of time that drug molecules attach to their target protein varies greatly and impacts the protein’s behaviour and drug efficacy. In a new study, scientists in Finland have identified some causal factors for this variance, with the hope it will bring clarity for drug developers.
Researchers have established a list of compounds that effect cytokine storms that could reduce mortality in COVID-19 patients.
Scientists in Japan have developed a credible heart cell model for arrhythmogenic cardiomyopathy and observed a positive response in the condition using PKP2 gene therapy.
Benefits and key considerations of using human iPSC-derived disease models in drug discovery.
In mice, researchers have shown that δ-valerobetaine plays a role in neurocognitive ability, making the metabolite a target for age-related memory loss.
Researchers have developed a new drug delivery system using virus-like particles to successfully transport gene-editing proteins in pre-clinical studies.
Avacta Group announced that the chemotherapy candidate AVA3996 will be developed with a view to a first-in-human clinical trial beginning in 2023.
Representing a breakthrough in better understanding how tau proteins cause neurodegenerative disease, scientists have mapped the tau interactome.
Research has shown that memory T cells formed following SARS-CoV-2 infection or mRNA vaccination respond to the Omicron variant.
New Bristol Myers Squibb research has revealed details about the structure of the protein receptor CD47, which helps protect cells from the human immune system.
Researchers have developed rapamycin-loaded nanocarriers capable of targeting cells related to pancreatic islet transplants without suppressing wider immune responses.
Sino Biological has announced that its new location in Houston, Texas, is now open, expanding the company geographically.
During investigations into the tropical disease Buruli ulcer, researchers have instead identified a promising new avenue for potential treatments for multiple myeloma.